Sie suchten nach: murine (Englisch - Maltesisch)

human anti-murine antibodies
antikorpi umani kontra proteini tal-ġrieden

hypersensitivity to rituximab or to other murine-derived proteins.
sensittività eċċessiva għal rituximab jew għal xi proteini oħra derivati mill-ġrieden

hypersensitivity to eculizumab, murine proteins or to any of the excipients.
sensittività eċċessiva għal eculizumab, proteini tal- ġrieden jew għal xi sustanzi mhux attivi.

hypersensitivity to alemtuzumab, to murine proteins or to any of the excipients.
sensittività eċċessiva għal alemtuzumab, għall-proteini murini jew għal xi sustanzi mhux attivi

they exhibit selectivity for human but not murine interferons, suggesting species specificity.
huma juru selettività għall-interferoni tal- bniedem iżda mhux għal dawk tal-ġrieden, li jagħti ħjiel ta’ speċifiċità għall-ispeċi.

patients who have previously received murine monoclonal antibody products are more likely to have hama.
pazjenti li inghatalhom qabel dawn il-protejini ghandhom possibilita’ akbar li jizviluppaw hama.

patients may have allergic or hypersensitivity reactions to mabcampath and to murine or chimeric monoclonal antibodies.
pazjenti jista’ jkollhom reazzjonijiet allerġiċi jew ta’ sensittività eċċessiva għal mabcampath u għal antikorpi monoklonali murini jew kimeriċi.

hypersensitivity to trastuzumab, murine proteins, or to any of the excipients listed in section 6.1
sensittività eċċessiva għal trastuzumab, proteini tal-ġrieden, jew għal kwalunkwe wieћed mill- eċċipjenti elenkati fis-sezzjoni 6.1.

ofatumumab is a human monoclonal antibody produced in a recombinant murine cell line (ns0).
ofatumumab huwa antikorp monoklonali uman magħmul f’linja ta’ ċelluli murine rikombinanti (ns0).

dabrafenib is a substrate of human p-glycoprotein (pgp) and murine bcrp in vitro.
dabrafenib huwa substrat ta’ p-glycoprotein (pgp) tal-bniedem u bcrp tal-firien in vitro.

one patient had both a statistically significant upward trend and displayed a sustained peak in anti-murine igg antibody level.
pazjent wieħed kellu kemm xejra 'l fuq statistikament sinifikanti kif ukoll wera quċċata sostnuta fil- livell tal- antikorpi kontra l- igg tal- ġrieden.

after use of zevalin, patients must generally be tested for hama before any further treatment with murine-derived proteins.
wara l-użu ta’ zevalin, ġeneralment il-pazjenti għandhom jiġu ttestjat għal hama qabel kull kura oħra b’proteini li ġejjin mill-ġrieden.

this humanised monoclonal antibody is composed of human (95%) and murine (5%) antibody sequences.
dan l-anti-korp uman monoklonali huwa magħmul minn sekwenzi ta’ anti-korpi umani (95%) u tal-ġrieden (5%).

besilesomab is an anti-granulocyte monoclonal antibody (bw 250/183), produced in murine cells.
besilesomab huwa antikorp monoklonali antigranuloċita (bw 250/183), maħluq f’ċelluli murini.

each 3 ml vial contains 0.31 mg sulesomab (immu-mn3 murine fab-sh antigranulocyte monoclonal antibody fragments).
kull fjala fiha 0.31mg sulesomab (immu-mn3 murine fab’-sh antigranulocyte monoclonal antibody fragments)

efalizumab is an igg1 kappa immunoglobulin, containing human constant region sequences and murine light- and heavy-chain complementary determining region sequences.
efalizumab huwa igg1 kappa immunoglobulina, bi sekwenzi kostanti uman u sekwenzi komplimentari ta’ katini ħfif u tqal, murini.

dinutuximab is a chimeric human/mouse monoclonal antibody produced in a murine myeloma cell line (sp2/0) by recombinant dna technology.
dinutuximab hu antikorp kimeriku monoklonali uman/tal-ġrieden prodott f’razza ta’ ċelluli tal-majeloma murine (sp2/0) minn teknoloġija ta’ dna rikombinanti.

a murine anti- murine il-1 beta antibody had no undesirable effects on fertility in male or female mice (see section 5.3).
l-antikorp antimurin tal-ġrieden il-i beta ma kellux effetti mhux mixtieqa fuq il-fertilità fost ġrieden irġiel jew nisa (ara sezzjoni 5.3).

each 3 ml vial contains 0.31 mg sulesomab (immu-mn3 murine fab-sh antigranulocyte monoclonal antibody fragments) for the preparation of 99mtc labelled leukoscan.
kull fjala fiha 0.31 mg sulesomab (immu-mn3 framment ta antikorpu monoklonali antigranulocita) ghall-preparazzjoni ta’ leukoscan immarkat bil tc99m.

the active substance is sulesomab each 3 ml vial contains 0.31 mg sulesomab (immu-mn3 murine fab′ -sh antigranulocyte monoclonal antibody fragments).
- kull fjala fiha 0. 31mg sulesomab (immu- mn3 murine fab ’ - sh antigranulocyte monoclonal